Product NDC: | 51293-607 |
Proprietary Name: | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
Non Proprietary Name: | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
Active Ingredient(s): | 5; 2.5 mg/1; mg/1 & nbsp; Chlordiazepoxide Hydrochloride and Clidinium Bromide |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 51293-607 |
Labeler Name: | ECI Pharmaceuticals LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | |
Marketing Category: | UNAPPROVED DRUG OTHER |
Start Marketing Date: | 20110504 |
Package NDC: | 51293-607-01 |
Package Description: | 100 CAPSULE in 1 BOTTLE (51293-607-01) |
NDC Code | 51293-607-01 |
Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
Package Description | 100 CAPSULE in 1 BOTTLE (51293-607-01) |
Product NDC | 51293-607 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 20110504 |
Marketing Category Name | UNAPPROVED DRUG OTHER |
Labeler Name | ECI Pharmaceuticals LLC |
Substance Name | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE |
Strength Number | 5; 2.5 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Benzodiazepine [EPC],Benzodiazepines [Chemical/Ingredient],Anticholinergic [EPC],Decreased Parasympathetic Acetylcholine Activity [PE],GI Motility Alteration [PE],Digestive/GI System Activity Alteration [PE],Cholinergic Antagonists [MoA] |